AstraZeneca on Wednesday said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer.
The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.
Lynparza, jointly developed with U.S.-based Merck & Co , was approved last year by the U.S. Food and Drug Administration as a treatment for early-stage breast cancer with certain mutations.
Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.
https://finance.yahoo.com/news/rpt-1-astrazeneca-says-drug-065915344.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.